The FDA is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD) – including certain formulations of amphetamine and methylphenidate – to warn about the risk of weight loss and other adverse reactions (side effects) in patients yo

http://www.fda.gov/safety/medical-product-safety-information/extended-release-stimulants-adhd-fda-drug-safety-communication-fda-requires-expanded-labeling-about